|
|
Article: Morria Biopharmaceuticals Plc. Announces Publication of the Results of Its Human Pilot Study in Contact Dermatitis Patients of MRX1, a Novel First-in-Class MFAID.
- Article from:
- Business Wire
- Article date:
- February 14, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LONDON -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today the publication of results from its human pilot clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX1. The results of the study are published in the upcoming edition of the International Journal of Immunopathology and Pharmacology. MRX1 was tested in a double-blind placebo controlled study on 11 contact dermatitis patients at the Hadassah University Hospital in Israel. The pilot clinical study findings show that a topical preparation of MRX1, applied twice daily for 14 days, scored 69% ...